Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice.

abstract：:The objective of this study was to evaluate the effectiveness and tolerability of aripiprazole use in child and adolescent psychiatric inpatients. This was a naturalistic, retrospective evaluation of the discharged patients treated with aripiprazole on the child and adolescent unit at the Austin State Hospital. To be ...

journal_title：International clinical psychopharmacology

authors： Gibson AP,Crismon ML,Mican LM,Fischer C

更新日期：2007-03-01 00:00:00

abstract：:In a total population of patients with a schizophrenic syndrome, the amount of antipsychotic drugs during a defined period was studied. Doses of antipsychotics were higher in males than in females, low to moderate in most patients, and decreased with the duration of illness. There was a significant negative correlatio...

journal_title：International clinical psychopharmacology

authors： Lindström E,Widerlöv B,von Knorring L

更新日期：1996-12-01 00:00:00

abstract：:The chronic course of major depressive disorder (MDD) often impedes the ability of patients to achieve full remission. Return of full functioning is a critical goal of antidepressant pharmacotherapy as the presence of residual depressive symptoms is associated with an increased risk of relapse. Treatment guidelines re...

journal_title：International clinical psychopharmacology

authors： Carrasco JL,Kornstein SG,McIntyre RS,Fayyad R,Prieto R,Salas M,Mackell J,Boucher M

更新日期：2016-05-01 00:00:00

abstract：:The SSRIs differ from each other with regard to their chemical structure, their pharmacokinetics and their potential for causing pharmacokinetic interactions through inhibition of species of the cytochrome P450 enzyme system. Cytochrome P450 (CYP) is a group of more than 30 different heme containing proteins in humans...

journal_title：International clinical psychopharmacology

authors： Brøsen K

更新日期：1998-09-01 00:00:00

abstract：:We report the case of a patient with schizophrenia who developed urinary hesitancy and eventually urinary retention, 6 months after continuous treatment with ziprasidone; he had been administered no other medication during this time. The micturition difficulties resolved immediately upon discontinuation of ziprasidone...

journal_title：International clinical psychopharmacology

authors： Xomalis D,Bozikas VP,Garyfallos G,Nikolaidis N,Giouzepas J,Fokas K

更新日期：2006-01-01 00:00:00

abstract：:The effect of adjunctive fluoxetine on negative schizophrenic symptoms was evaluated in 34 chronic schizophrenic in-patients on maintenance therapy with neuroleptics. They received randomly, on a double-blind basis, fluoxetine (20 mg/day) or placebo for 12 weeks. In the fluoxetine group, three patients dropped out bec...

journal_title：International clinical psychopharmacology

authors： Spina E,De Domenico P,Ruello C,Longobardo N,Gitto C,Ancione M,Di Rosa AE,Caputi AP

更新日期：1994-01-01 00:00:00

abstract：:Neuroleptics are of established efficacy in mania. Controlled data on the use of olanzapine in mania is however, absent. In this study, 30 patients meeting DSM-IV criteria for mania were randomly allocated to receive either olanzapine or lithium in a 4 week double-blind randomized controlled design. There were no sign...

journal_title：International clinical psychopharmacology

authors： Berk M,Ichim L,Brook S

更新日期：1999-11-01 00:00:00

abstract：:Twelve normal weight healthy male volunteers participated in a double-blind, placebo-controlled trial of the effects of d- and l-fenfluramine, d-amphetamine, and the interactions between the two isomers of fenfluramine with amphetamine, on cortisol secretion. d-Fenfluramine and d-amphetamine in combination produced th...

journal_title：International clinical psychopharmacology

authors： Feeney S,Goodall E,Silverstone T

更新日期：1993-10-01 00:00:00

abstract：:The effect of the antipsychotic drug trifluoperazine (TFP) on the in-vitro growth of 50 clinical isolates of Mycobacterium tuberculosis was tested. Of these isolates, 29 were susceptible to all five of the antitubercular drugs isoniazid, rifampicin, streptomycin, ethambutol and pyrazinamide, and 21 were resistant to o...

journal_title：International clinical psychopharmacology

authors： Gadre DV,Talwar V,Gupta HC,Murthy PS

更新日期：1998-05-01 00:00:00

abstract：:There is uncertainty with regard to the appropriate use of metformin for the prevention and management of second-generation antipsychotic-induced weight gain and metabolic abnormalities. We aim to systematically review the primary literature and to provide recommendations with regard to the use of metformin in psychia...

journal_title：International clinical psychopharmacology

authors： Newall H,Myles N,Ward PB,Samaras K,Shiers D,Curtis J

更新日期：2012-03-01 00:00:00

abstract：:Long-term treatment with benzodiazepines (BZD) should be avoided in dementia patients because of an increased risk of adverse events. We evaluated how continuously dementia patients were prescribed BZD over 12 months. For this observational study, we used claims data from a large German public sickness fund for 2014 a...

journal_title：International clinical psychopharmacology

authors： Hessmann P,Jan Zeidler,Neubauer S,Abdel-Hamid M,Stahmeyer J,Eberhard S,Wolff-Menzler C,Wiltfang J,Kis B

更新日期：2018-09-01 00:00:00

abstract：:Methylamphetamine given intravenously as a single 15 mg dose led to a pronounced elevation of mood in 7 out of 21 depressed patients compared to a control injection of sterile water administered on another occasion in random order under double-blind conditions. All 7 responders experienced an increase of VAS self-rati...

journal_title：International clinical psychopharmacology

authors： Cookson J,Silverstone T

更新日期：1986-04-01 00:00:00

abstract：:Vilazodone is a potent selective serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder in adults. To assess the efficacy of vilazodone across a range of symptoms and severities of depression, data from two phase III, 8-week, randomized, double-bl...

journal_title：International clinical psychopharmacology

authors： Khan A,Sambunaris A,Edwards J,Ruth A,Robinson DS

更新日期：2014-03-01 00:00:00

abstract：:A variety of cognitive impairments can be observed in patients with schizophrenia, including substantial reductions in the intelligence quotient (IQ). I propose that these impairments can be best understood in terms of the abnormal processes underlying the signs and symptoms manifested by the patient at the time of th...

journal_title：International clinical psychopharmacology

authors： Frith CD

更新日期：1995-09-01 00:00:00

abstract：:Duloxetine, an inhibitor of serotonin and norepinephrine reuptake, has been approved for the treatment of major depressive disorder. In this analysis, data from eight, double-blind, placebo-controlled duloxetine trials were pooled, and the response to duloxetine treatment (40-120 mg/day) was compared between patients ...

journal_title：International clinical psychopharmacology

authors： Perahia DG,Kajdasz DK,Royer MG,Walker DJ,Raskin J

更新日期：2006-09-01 00:00:00

abstract：:One hundred and sixty patients with a primary diagnosis of obsessive-compulsive disorder were enrolled in a multicentre, randomized, double-blind, placebo-controlled study of fluvoxamine. After a placebo washout phase, patients were randomized to treatment with placebo or fluvoxamine (100-300 mg/day) for 10 weeks. Sev...

journal_title：International clinical psychopharmacology

authors： Goodman WK,Kozak MJ,Liebowitz M,White KL

更新日期：1996-03-01 00:00:00

abstract：:Since the introduction in 1993 of the novel serotonin-dopamine antagonist antipsychotic risperidone, over 12 million patient-months of exposure to the drug have been accumulated. Further studies have confirmed the efficacy of risperidone across a broad range of patients with schizophrenia who were not represented in t...

journal_title：International clinical psychopharmacology

authors： Gutierrez-Esteinou R,Grebb JA

更新日期：1997-09-01 00:00:00

abstract：:The effects of risperidone on affective symptoms were determined by an analysis of pooled data from six double-blind trials of risperidone versus haloperidol in 1254 patients with chronic schizophrenia. Symptoms indicating mania were assessed by the Positive and Negative Syndrome Scale (PANSS) excitement and grandiosi...

journal_title：International clinical psychopharmacology

authors： Peuskens J,Van Baelen B,De Smedt C,Lemmens P

更新日期：2000-11-01 00:00:00

abstract：:On the basis of numerous previous studies, the serotonergic system plays a role in the pathogenesis of obsessive-compulsive disorder (OCD) and effective agents in this pathway, such as 5-hydroxytryptophan, can potentially contribute to treatment of patients with this disorder. Evaluating the efficacy of 5-hydroxytrypt...

journal_title：International clinical psychopharmacology

authors： Yousefzadeh F,Sahebolzamani E,Sadri A,Mortezaei A,Aqamolaei A,Mortazavi SH,Shalbafan MR,Ghaffari S,Alikhani R,Mousavi SB,Naderi S,Shamabadi A,Jalilevand S,Akhondzadeh S

更新日期：2020-09-01 00:00:00

abstract：:The effects of moclobemide, 450 mg/day, on sleep were investigated in 12 patients with major depression. The study was carried out over six weeks, divided into three periods: (1) treatment for one week with placebo and measurement to obtain baseline values; (2) treatment with moclobemide for four weeks; and (3) one we...

journal_title：International clinical psychopharmacology

authors： Minot R,Luthringer R,Macher JP

更新日期：1993-01-01 00:00:00

abstract：:DEPRESS (Depression Research in European Society) is the first large pan-European survey of depression in the community. A total of 13359 of the 78463 adults who participated in screening interviews across six countries were identified as suffering from depression, a 6-month prevalence of 17%. Major depression account...

journal_title：International clinical psychopharmacology

authors： Lépine JP,Gastpar M,Mendlewicz J,Tylee A

更新日期：1997-01-01 00:00:00

abstract：:Scientific, professional, and governmental bodies have in recent years intensified efforts to formulate guidelines for the treatment of depression with the goal that medical practice should comply with these standards and thus improve patient care. 'Evidence-based medicine' demands that medical practice should explici...

journal_title：International clinical psychopharmacology

authors： Linden M

更新日期：1999-06-01 00:00:00

abstract：:Reports of decreased mortality among patients with schizophrenia who use clozapine may be biased if clozapine is prescribed to relatively healthy patients and if intensive monitoring during its use prevents (under-treatment of) somatic disorder. We aimed to assess whether there is a difference in: (1) somatic comorbid...

journal_title：International clinical psychopharmacology

authors： van der Zalm Y,Termorshuizen F,Sommer IE,Selten JP

更新日期：2020-01-01 00:00:00

abstract：:While the incidence and psychiatric correlates of violent trauma among children and adolescents have been well documented, there is less data on the specific ways in which girls are affected by violence. The present review examines current knowledge of the prevalence and effects of violent trauma on female children an...

journal_title：International clinical psychopharmacology

authors： Kaminer D,Seedat S,Lockhat R,Stein DJ

更新日期：2000-11-01 00:00:00

abstract：:Good evidence now exists for a therapeutic action of carbamazepine (CBZ) both in acute mania and in the prophylaxis of manic depression. Comparison with other existing therapies and incidence of adverse effects in psychiatric patients also deserve more clinical research. This paper reviews these clinical issues and th...

journal_title：International clinical psychopharmacology

authors： Elphick M

更新日期：1988-07-01 00:00:00

abstract：:In recent years the efficacy of new antipsychotics has been investigated through a number of randomized controlled trials. This paper considers some methodological flaws that affect these studies and proposes possible solutions. The final goal is the implementation of a new generation of trials with the aim of demonst...

journal_title：International clinical psychopharmacology

authors： Barbui C,Garattini S

更新日期：1999-03-01 00:00:00

abstract：:Depressive symptoms are associated with poor outcomes, increased risk of relapse, and high suicide rates in patients with schizophrenia and schizoaffective disorder. This randomized, open-label, parallel-group, flexible-dose study (NCT00640562) assessed the efficacy of quetiapine extended release (XR) versus risperido...

journal_title：International clinical psychopharmacology

authors： Di Fiorino M,Montagnani G,Trespi G,Kasper S

更新日期：2014-05-01 00:00:00

abstract：:Most depressive disorders can be viewed as recurrent conditions that may reduce quality of life and productivity. Results of controlled clinical trials indicate that patients should receive 4-6 months of continuation therapy after remission of the acute phase of the illness. Patients at risk of recurrent episodes, how...

journal_title：International clinical psychopharmacology

authors： Kasper S

更新日期：1993-01-01 00:00:00

abstract：:The interactions between warfarin and antidepressants can have potentially serious consequences resulting from enhanced or reduced anticoagulant activity. Information about such interactions was obtained from a Medline and hand search of the published literature, and by directly contacting manufacturers. The different...

journal_title：International clinical psychopharmacology

authors： Duncan D,Sayal K,McConnell H,Taylor D

更新日期：1998-03-01 00:00:00

abstract：:We report that perospirone may have had positive effects on the obesity of three patients with schizophrenia and on the fasting blood sugar (FBS) and HbA1C of two of them who had type 2 diabetes mellitus. ...

journal_title：International clinical psychopharmacology

authors： Nishida M,Nakamura M

更新日期：2004-01-01 00:00:00